相关实验视频
Updated: Jun 29, 2025

Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
在KCNH2的特定人群变异使患者在二甲美西宁-皮皮拉奎因治疗时倾向于延迟腹腔再极化
Mahamadou D Camara1,2, Yitian Zhou1, Antoine Dara2
1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
遗传因素对抗疟疾药物piperaquine的心脏安全风险产生影响. 特定的KCNH2基因变异显著增加了QT延长,确定了患者风险分层的潜在生物标志物.
科学领域:
- 药物基因组学 药物基因组学
- 心血管安全心血管安全
- 治疗疟疾的方法
背景情况:
- 狄氏甲胺素-皮佩拉奎因是关键的抗疟疾药物,但皮佩拉奎因抑制Kv11.1通道 (hERG) 引发了心脏安全问题.
- 基因变异在KCNH2 (编码Kv11.1) 中对调节皮佩拉基因诱导的QT延长的作用尚不清楚.
研究的目的:
- 调查KCNH2.2在种群规模上的遗传变异性.
- 在疟疾患者中确定可预测皮佩拉奎因介导的QT延长的遗传生物标志物.
主要方法:
- 在141,614个个体中分析KCNH2遗传变异,使用计算算法开发一个KCNH2特定的集体分类器.
- 在293名马里疟疾患者中测序KCNH2并将遗传数据与 piperaquine 暴露后的心电图变化相关联.
主要成果:
- 鉴定出1007种异常KCNH2变异,包括116种假定有害的误解变异.
- 两种常见的KCNH2变异 (rs1805121,rs41314375) 与显著更高的QT延长有关 (ΔQTc为41.8毫秒和61毫秒).
- 罕见的变异与三名患者的临床相关的延迟腹腔再极化有关.
结论:
- 种群规模的KCNH2变异性影响piperaquine的心脏安全性.
- 遗传生物标志物可以识别患有 piperaquine 诱导的 QT 延长风险较高的患者,帮助优化治疗.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antihypertensive Drugs: Potassium-Sparing Diuretics

